Roche Holding AG (RHHBY)
| Market Cap | 328.28B +35.1% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.21 |
| Forward PE | 15.68 |
| Dividend | 0.97 (1.86%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 166,514 |
| Open | 51.11 |
| Previous Close | 49.00 |
| Day's Range | 51.11 - 51.84 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 56.66 (+9.45%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 9.45% from the latest price.
News
Roche reports developing PCR test for Ebola within six days
Roche (RHHBY) announced that it developed a Research Use Only molecular PCR test, via its subsidiary TIB MOLBIOL, for use on the LightCycler 480 I & II Systems, LightCycler PRO…
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
New Roche test targeting detection of Bundibugyo virus supports efforts to address critical need during ongoing outbreaks 1 Roche's unique outbreak response capabilities enabled rapid development of t...
Roche chairman likens US tariff policy to 'blackmail'
The chairman of Swiss pharmaceutical giant Roche hit out at U.S. tariff policies on Thursday, likening them to "blackmail", and said protectionism by the United States and China was the firm's bigge...
Ideaya Biosciences announces IDE892 collaboration with Roche
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Roche (RHHBY) to evaluate the efficacy and safety of IDE892 in combination with Roche’s RG6505, a pan-RAS inhibito...
Roche Holding AG Transcript: Investor update
Oncology and hematology delivered strong Q1 growth, led by breast and lung cancer therapies and pipeline innovation. Giredestrant showed significant efficacy in adjuvant breast cancer, with multiple ongoing trials to expand its use. Divarasib and other RAS-targeted therapies are advancing, with a focus on combination strategies and new modalities.
Roche Holding AG Slides: Investor update
Roche Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Genentech announces FDA acceptance of giredestrant NDA under Priority Review
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s new drug application, or NDA, under Priority Review for giredestrant, an investigational oral selective estrogen...
FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--FDA accepts NDA for Genentech's giredestrant in ER+ early-stage breast cancer.
FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Prio...
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association®...
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 202...
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more th...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical ...
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Monda...
FDA approves Genentech’s Tecentriq for adjuvant muscle-invasive bladder cancer
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Tecentriq and Tecentriq Hybreza as an adjuvant treatment for adult patients with…
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
The drugmaker's on-market pharma portfolio, together with drugs for lupus, breast cancer and multiple sclerosis, should offset generic competition until 2030, Chief Executive Thomas Schinecker said.
Roche receives CE Mark for Elecsys pTau217
Roche (RHHBY) announced that it has received CE Mark for Elecsys pTau217, a blood test developed in collaboration with Eli Lilly and Company (LLY) and designed to measure the phosphorylated…
Roche Holding AG Transcript: Roche Diagnostics Day 2026
The event outlined a strategy centered on innovation, digital integration, and targeted growth in high-burden disease areas. Key launches like AXELIOS sequencing and CGM are set to drive mid to high single-digit sales growth, with profit outpacing sales, supported by strategic acquisitions and a robust pipeline.
Roche Holding AG Slides: FY 2026
Roche Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Roche gets second European approval for Alzheimer's test
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and design...
Roche announces agreement to acquire PathAI
Roche (RHHBY) announced that it has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital pathology and AI-powered technology for pathology laboratories and the...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...